Search Results
Your search for early matches 10493 pages
Showing 2101 - 2150Decrease in Breast Cancer Mortality Rate Continues, but Gap Persists for Black Women: From American Cancer Society Report
Although breast cancer death rates dropped by 43% from 1989 to 2020, Black women continue to be 40% more likely to die of the disease, despite a lower incidence, according to findings outlined in the American Cancer Society’s report Breast Cancer Statistics, 2022, and a companion study published by ...
ASCO and the African Organisation for Research and Training in Cancer Announce Innovative Collaboration to Advance Cancer Research in Africa
ASCO and the African Organisation for Research and Training in Cancer (AORTIC) have signed a memorandum of understanding (MOU) committing the two organizations to collaborate to advance cancer research in Africa. Harnessing the respective programs, leaders, and member networks of both...
Managing Lymphomas in the Future: Some Bright Spots Are Emerging
Although standard therapies may provide long-lasting remissions for many patients with various subtypes of lymphoma, there is a critical need for new strategies for the sizable high-risk subset. At the 2022 Pan Pacific Lymphoma Conference, four experts in the field described future therapies for...
First-Line Maintenance With Olaparib Improved Overall Survival in Subsets of Patients With Advanced Ovarian Cancer in Two Phase III Trials
First-line maintenance therapy with olaparib extended survival beyond historical expectations in some women with newly diagnosed advanced ovarian cancer, according to two phase III studies presented at the European Society for Medical Oncology (ESMO) 2022 Congress.1,2 In the SOLO1 trial,1 more...
Expert Point of View: Mary O’Brien, MD
Formal discussant of the KEYNOTE-189 and KEYNOTE-407 trials, Mary O’Brien, MD, Head of the Lung Unit, Royal Marsden Hospital, NHS Foundation Trust, London, found that both studies showed consistent gains in overall and progression-free survival with pembrolizumab/chemotherapy, but she expressed...
Cancer and Fertility Preservation: Will New Laws Leave Patients Without Options?
The legal climate surrounding reproductive health care and fertility preservation has changed drastically since the June 2022 Supreme Court decision to overturn Roe v Wade, which revoked the constitutional right to abortion. With this ruling, individual state legislatures are now able to pass laws...
Saul A. Rosenberg, MD, FASCO, a Pioneer in the Field of Lymphoma, Dies at 95
For anacademic oncologist, there is no greater reward than to be part of the clinical research that turns a fatal cancer into a highly treatable disease. Saul A. Rosenberg, MD, FASCO, was one such researcher who pioneered advances in the diagnosis, treatment, and understanding of lymphoma,...
Living With Metastatic Breast Cancer
After my first breast cancer diagnosis, in 2010, the odds for a cure were seemingly all weighted in my favor. A routine mammogram screening had picked up a small—less than 1 cm—mass in my right breast, and a tissue biopsy confirmed it was stage I estrogen receptor–positive breast cancer. I had no...
The Development of Geriatric Oncology in France: An Outside View
With the aging of the world population, geriatric oncology is becoming a mainstay. Over the past year in The ASCO Post, we published a couple of articles on the history of oncology, including one on the history of geriatric oncology in the United States and Europe. Our goal was to promote a...
Massey Cancer Center and VCU Health Appoint Paula M. Fracasso, MD, PhD, FACP, to Leadership Roles
Paula M. Fracasso, MD, PhD, FACP, has joined Virginia Commonwealth University (VCU) Massey Cancer Center and VCU Health as Deputy Director of the cancer center and Senior Vice President of the cancer service line at VCU Health. The cancer service line is a collaborative model designed to fulfill...
Sublobar Resection for Small, Early-Stage NSCLC: Establishing a New Standard of Care?
After a nearly 20-year wait, the results are finally in: sublobar surgery has been found to be noninferior to lobectomy and may be the new standard of care of patients with small, early-stage non–small cell lung cancer (NSCLC). Results of the phase III Alliance trial, presented at the International ...
COSMIC-313: Triplet Therapy Is Active in Renal Cell Carcinoma, but Toxicities Pose a Challenge
The addition of cabozantinib to nivolumab plus ipilimumab prolonged progression-free survival in untreated intermediate-risk patients with advanced renal cell carcinoma (RCC), according to the first results of the phase III COSMIC-313 trial. These findings were presented as a Presidential Symposium ...
Health-Related Quality of Life for Survivors of Metastatic Prostate Cancer
Survivors of prostate cancer originally diagnosed with metastatic disease may experience significantly worse health-related quality of life than those diagnosed with early-stage disease and individuals without a cancer history across all domains, according to a new study by Zheng et al published in ...
Historical Housing Discrimination May Adversely Affect Contemporary Colon Cancer Care and Outcomes
Recent findings showed that historical housing discrimination may negatively affect contemporary care and outcomes for patients diagnosed with colon cancer, according to a study by Hussaini et al in the Journal of Clinical Oncology. The findings were also presented at the 2022 ASCO Quality Care...
Study Investigates Potential Embryonic Origin of Medulloblastomas
Medulloblastomas may exist in a premalignant form at birth after initially developing during the first or second trimester of pregnancy, according to a new international study published by Hendrikse et al in Nature. As medulloblastomas typically present around age 7, the team’s discovery is the...
Real-World Evidence Confirms Survival Benefit of Durvalumab in Locally Advanced Non–Small Cell Lung Cancer
In locally advanced non–small cell lung cancer (NSCLC), immunotherapy consolidation with the PD-L1 inhibitor durvalumab improved overall survival in the PACIFIC trial,1 thus leading to its use after chemoradiotherapy as a standard of care. Real-world evidence of durvalumab’s effect on overall and...
IMpower010: Early Survival Data Favor Atezolizumab Over Best Supportive Care in Resected NSCLC With PD-L1 Expression ≥ 50%
Early results from the IMpower010 trial showed an overall survival trend favoring adjuvant atezolizumab vs best supportive care for patients with PD-L1–positive (tumor expression ≥ 1%), stage II–IIIA (UICC/AJCC staging system, 7th ed), resected non–small cell lung cancer (NSCLC). These data were...
Highlights From the IASLC 2022 World Conference on Lung Cancer
Over the past few years, we have seen rapid and dramatic transformation in the therapeutic landscape of non–small cell lung cancer (NSCLC). We have had multiple new targeted therapies for newer targets (previously undruggable targets) and better diagnostic strategies to workup patients to realize...
National Lung Screening Trial Results Highlight Importance of Lifelong Follow-up
Approximately 6% of patients with stage I to III lung cancer develop second primary lung cancer within 5 years of their initial diagnosis, according to research presented at the International Association for the Study of Lung Cancer (IASLC) 2022 World Conference on Lung Cancer.1 Analysis of data...
NELSON vs NLST: Nodule Management Based on Volumetry Shows Increased Benefits
Lung cancer screening has been shown to significantly reduce lung cancer mortality, but some management protocols have more benefit than others, according to data presented at the International Association for the Study of Lung Cancer 2022 World Conference on Lung Cancer (WCLC).1 Although the...
DART Trial: Concurrent Radiotherapy Plus Durvalumab Active in Older Patients With Locally Advanced Lung Cancer
Interim results of a phase II study have demonstrated the safety and feasibility of treating elderly and frail patients with locally advanced non–small cell lung cancer (NSCLC) with the monoclonal antibody durvalumab during and after radiation therapy, without chemotherapy. The results of a...
Study Focuses on Molecular Details of Precancerous Clonal Outgrowth in Blood Cells
A common, spontaneous mutation in blood stem cells, which has been linked to a higher risk of blood cancer and cardiovascular disease, may promote these diseases by altering the stem cells’ programming of gene activity and the mix of blood cells they produce, according to a study co-led by...
Risks Associated With Sinoatrial Node Radiation Dose in Patients With Lung Cancer Receiving Definitive Chemoradiotherapy
In a Korean single-institution retrospective cohort study reported in JAMA Oncology, Kim et al found that higher sinoatrial node radiation doses were associated with an increased risk of atrial fibrillation and poorer survival in patients with limited-stage small cell lung cancer (SCLC) and locally ...
Inflammatory Markers and Clinical Decline After Adjuvant Chemotherapy in Older Women With Breast Cancer
As reported in the Journal of Clinical Oncology by Ji et al, the HOPE study (Hurria Older Patients [HOPE] with Breast Cancer Study) has shown that older women categorized as robust prior to adjuvant chemotherapy are at risk for clinical decline postchemotherapy, with high baseline levels of the...
Association of Breast Cancer Recurrence in Patients Achieving pCR With vs Without Residual DCIS After Neoadjuvant Chemotherapy
In a retrospective analysis from the neoadjuvant I-SPY2 trial reported in JAMA Surgery, Osdoit et al found that among patients with breast cancer achieving pathologic complete response (pCR), there were no significant differences in treatment outcomes according to the presence or absence of...
Lasker Foundation Announces 2022 Lasker Award Winners
On September 28, the Lasker Foundation announced the winners of the 2022 Albert Lasker Basic Medical Research Award, the 2022 Lasker~DeBakey Clinical Medical Research Award, and the 2022 Lasker~Bloomberg Public Service Award. Albert Lasker Basic Medical Research Award Richard O. Hynes, PhD, of the...
Constitutional BRCA1 Methylation and Risk of Triple-Negative Breast Cancer and Ovarian Cancer
In a case-control study within the U.S. Women’s Health Initiative (WHI) study population reported in JAMA Oncology, Lønning et al found that BRCA1 promoter methylation identified in white blood cells was associated with increased risks of incident triple-negative breast cancer and high-grade serous ...
Marleen Kok, MD, PhD, on Triple-Negative Breast Cancer: Nivolumab Monotherapy or in Combination Therapy
Marleen Kok, MD, PhD, of The Netherlands Cancer Institute in Amsterdam, discusses the initial results from the BELLINI trial, which tested whether short-term preoperative nivolumab, either as monotherapy or in combination with low-dose doxorubicin or novel immunotherapy combinations, can induce...
Financial Burden of High-Cost Targeted Oral Anticancer Drugs Among Medicare Patients
In a study reported in JCO Oncology Practice, Li et al identified elements of increasing financial burden associated with the use of high-cost targeted oral anticancer drugs among Medicare patients between 2011 and 2016. The study used data from the Surveillance, Epidemiology, and End Results...
Unhealthy Gut May Set the Stage for Breast Cancer to Spread, Preclinical Research Reveals
An unhealthy gut triggers changes in normal breast tissue that may help breast cancer metastasize, according to new, early research from the University of Virginia (UVA) Cancer Center published by Feng et al in Cancer Immunology Research. The researchers found that when the gut microbiome is...
Research Finds Medicaid Expansion Led to Decreases in Cancer Incidence and Mortality Rates
State-run Medicaid insurance, expanded in 2014 as part of the Affordable Care Act, has resulted in decreased metastatic cancer incidence rates as well as decreased overall cancer mortality rates, and has averted over 1,000 deaths due to cancer per year. About 12% of the improvements in cancer...
A Physicist Father Inspired a Love of Science in Oncology Researcher Stanton L. Gerson, MD
In this installment of the Living a Full Life series, Guest Editor Jame Abraham, MD, FACP, spoke with Stanton (“Stan”) L. Gerson, MD, Dean and Senior Vice President for Medical Affairs, School of Medicine, and Acting Director of the Case Comprehensive Cancer Center and National Center for...
Changing the Algorithm for Relapsed or Refractory Large B-Cell Lymphomas
Despite a significant potential for cure, relapsed and refractory large B-cell lymphomas (LBCL) comprise the most common cause of lymphoma-related mortality. Sequential relapses reflect the limits of repeated exposure to chemotherapy, even when delivered at high doses. More than 30 years ago,...
Determining Prognosis in Aggressive Lymphomas: Integrating Liquid Biopsy Into Imaging Assessment
The incorporation of blood-based measurements—ie, “liquid biopsies”—into imaging assessment may refine the accuracy of prognosis in aggressive lymphomas, as described by David Kurtz, MD, PhD, Assistant Professor in the Division of Oncology, Stanford University Medical Center, in a talk at the 2022...
Loïc Le Marchand, MD, PhD, MPH, Awarded 2022 AACR Lectureship on Science of Cancer Health Disparities
The American Association for Cancer Research (AACR) has announced Loïc Le Marchand, MD, PhD, MPH, as the recipient of the 2022 AACR Distinguished Lectureship on the Science of Cancer Health Disparities. Dr. Le Marchand presented his award lecture, “Translating Multiethnic Epidemiological Research...
Practice-Changing Studies, Important New Data, and More Clinical Oncology News From ESMO 2022, Paris
The European Society For Medical Oncology (ESMO) launched its annual congress, held September 9–13, 2022, just as this issue of The ASCO Post was going to press. Watch upcoming issues for comprehensive coverage of the live congress, following 2 years of virtual meetings and remote presentations due ...
NELSON vs NLST: Nodule Management Based on Volumetry Shows Increased Benefits
Lung cancer screening has been shown to significantly reduce lung cancer mortality, but some management protocols have more benefit than others, according to data presented at the International Association for the Study of Lung Cancer 2022 World Conference on Lung Cancer (WCLC).1 Although the...
IMpower010: Early Survival Data Favor Atezolizumab Over Best Supportive Care in Resected NSCLC With PD-L1 Expression ≥ 50%
Early results from the IMpower010 trial showed an overall survival trend favoring adjuvant atezolizumab vs best supportive care for patients with PD-L1–positive (tumor expression ≥ 1%), stage II–IIIA (UICC/AJCC staging system, 7th ed), resected non–small cell lung cancer (NSCLC). These data were...
What the Supreme Court’s Abortion Decision Means for Patients With Cancer and Their Clinicians
On June 24, 2022, the Supreme Court ruled in Dobbs v Jackson Women’s Health Organization (Dobbs)1 and overturned Roe v Wade and Planned Parenthood v Casey, which recognized a federal constitutional right to end a pregnancy up to the point of viability. This decision opened the door for states to...
Is Germline Testing Warranted for All Patients With Lung Cancer?
Germline testing may be warranted for all patients with lung cancer, according to research presented during the August 2022 ASCO Plenary Series by Renato G. Martins, MD, MPH, Chair of Hematology Oncology and Palliative Care at Virginia Commonwealth University Massey Cancer Center, Richmond.1 The...
AACR Cancer Progress Report 2022 Shows Cancer Mortality Rates Continue to Decline, but Challenges Remain
Advances in more effective treatment and early detection diagnostics, coupled with reductions in smoking rates, have resulted in a 32% decline in cancer mortality in the United States since 1991, translating into nearly 3.5 million lives saved, according to the newly released American Association...
September 24 Is World Cancer Research Day
September 24 is World Cancer Research Day, an initiative organized by a collaboration of professional societies, research organizations, and other institutions. In advance of the event, the following declaration was published in order to outline the goals of the initiative: Cancer is projected to...
Role of Circulating Tumor DNA in Early-Stage Colon Cancer
This is Part 1 of Updates in Colorectal Cancer, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Cathy Eng, Arvind Dasari, and Smitha Krishnamurthi discuss the role of circulating tumor DNA (ctDNA) in early-stage colon cancer....
Association of Distance to Treatment Facility, U.S. Region, and Insurance Status With Diagnosis of Advanced Colon Cancer
In a National Cancer Database analysis reported in JAMA Network Open, Brand et al found that patients with colon cancer who lived farther from their treatment facility and those with no insurance or Medicaid alone were more likely to present with advanced-stage disease. As stated by the...
Compliance of NCI-Designated Cancer Centers With January 2021 CMS Price Transparency Requirements
In a study reported in JAMA Surgery, Childers et al found that only one-third of hospitals with National Cancer Institute (NCI)-designated cancer center status were fully compliant with Centers for Medicare & Medicaid Services (CMS) price transparency requirements instituted in January 2021....
National Lung Screening Trial Results Highlight Importance of Lifelong Follow-up
Approximately 6% of patients with stage I to III lung cancer develop a second primary lung cancer within 5 years of their initial diagnosis, according to research presented at the International Association for the Study of Lung Cancer (IASLC) 2022 World Conference on Lung Cancer.1 Analysis of data...
Cost-Effectiveness of Chemotherapy Sequences in Metastatic Breast Cancer According to Prior Therapy Exposure
In a modeling study reported in the Journal of Clinical Oncology, Stephanie B. Wheeler, PhD, MPH, and colleagues identified the most cost-effective sequences of single-agent chemotherapy regimens among patients with endocrine-refractory or triple-negative metastatic breast cancer according to prior ...
Association of Neurofilament Light Chain Levels With ICANS Risk After CAR T-Cell Therapy
In a retrospective study reported in JAMA Oncology, Butt et al found significantly higher pretreatment neurofilament light chain levels in patients who did vs did not develop immune effector cell–associated neurotoxicity syndrome (ICANS) after CD19 chimeric antigen receptor (CAR) T-cell therapy....
Lung Cancer Screening Increases Percentage of Stage I Cases Detected, While Reducing Percentage of Stage IV Cases Detected
Implementing lung cancer screening at four diverse health-care systems resulted in an 8.4% increase in the number of stage I lung cancers detected and a 6.6% decrease in the detection of stage IV disease, according to research published by Vachani et al in the Journal of Thoracic Oncology. The...
Updated Results From the ADAURA Trial of Adjuvant Osimertinib in EGFR-Mutated NSCLC
Newly released results from the phase III ADAURA trial revealed that osimertinib yielded a 5.5-year median disease-free survival in the postsurgical treatment of patients with EGFR-mutated non–small cell lung cancer (NSCLC), and nearly three in four patients treated with adjuvant osimertinib were...
